Eradivir – Philip Low

Open Philanthropy made an investment of $1,000,000 to support development of drugs that inactivate influenza virus.

Open Philanthropy invested $1,000,000 in the company Eradivir that was founded to commercialize the discovery of a new class of antiviral drugs by Purdue biochemist Philip Low and collaborators.  The company has discovered small bispecific drugs that engage both cytotoxic immune cells and the virus. Binding of the drug to the virus leads to immune cells such as NK cells and activated macrophages to destroy the virus.  The approach can be considered a “platform technology” that is thought to be broadly applicable to other viruses.